[redacted]

[redacted]州康寧醫院股份有限公司

[redacted]zho[redacted]al Co., Ltd.

[redacted]pany incorporated in the People's Republic of China)

[redacted]St

( ) [illegible]

( ) [illegible]

( ) [illegible]

( ) [illegible]

( ) [illegible]

[illegible]

(i) Conduct an appropriate independent investigation into the issues raised by PwC, announce the findings and take appropriate remedial actions

[illegible]

( ) [illegible] **(Ms. Wang) (Alleged Area I)**- [illegible]

( )

(**Alleged Area II.**)- [illegible]

(**Actual Controller.**) [illegible]

[illegible]

[illegible] (**Minority Shareholders**) [illegible]

[illegible]

[illegible]

[illegible] (**Individuals of Interest**)

[illegible] (**Former Shareholder**)

[illegible] (**Indirect Investor**)

[illegible] (**Renovation Supplier**)-

[illegible]

[illegible]

( ) [illegible]

(.) [illegible]

(a) carrying out necessary changes to the Board and the management of the Company

[illegible] **(Ms. Jin)** [illegible] **(Mr. Chan)** [illegible] **(Mr. Wang)** [illegible]

(b) obtaining legal advice on the merits of commencing judicial proceedings for civil recovery against Ms. Wang regarding the personal interests she obtained under Alleged Area III

[illegible] **(Disgorged Gains)** [illegible] **(PRC Counsel)** [illegible]

[illegible]

(c) strengthening the use of external expert support

[illegible]

(d) reassessing accounting treatments related to the arrears of the impoverished patients identified in the Independent Investigation as well as the recoverability of the historical arrears, making necessary corrections of prior accounting errors, if any

[illegible]

(e) relevant treatment of the Indirect Investor, the Renovation Supplier and the Actual Controller involved in Alleged Area I and Alleged Area III

[illegible]

(f) strengthening the internal control system and compliance supervision of the Company

View of the Independent Investigation Committee

(ii) Demonstrate that there is no reasonable regulatory concern about the management integrity and/or the integrity of any persons with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

(iii) Conduct an independent internal control review and demonstrate that the Company has in place adequate internal controls and procedures to meet its obligations under the Listing Rules

[illegible]

[illegible]

Key Internal Control Issues	Rectifications
Entity-Level Review by COSO Framework	
Control Environment – Conflict of Interest Reporting Mechanism	

Key Internal Control Issues	Rectifications
Entity-Level Review by COSO Framework	
Control Environment – Succession Plan	
Risk Assessments – Anti-Money Laundering Mechanism	
Control Activities – Policies and Procedures	

Key Internal Control Issues	Rectifications
Activity-level review	
Revenue and Accounts Receivable Management – Bad Debt Provision	[illegible]

Key Internal Control Issues	Rectifications
Activity-level review	
	[illegible]

[illegible]

View of the Audit Committee

[illegible]

[illegible]

(iv) Publish all outstanding financial results required under the Listing Rules and address any audit modifications

[illegible]

(1) [illegible]

(2) [illegible]

(3) [illegible] (the "**2022 Interim Results**") [illegible]

(4) [illegible]

(5) [illegible] (the "**2022 Annual Results**") [illegible]

(6) [illegible]

[illegible]

(1) [illegible]

(2) [illegible]

(3) [illegible]

[illegible]

[illegible]

(.) [illegible]

(.) [illegible]

(.) [illegible]

(.) [illegible]

(.) [illegible]

(.) [illegible]

[illegible]

(v) Demonstrate the Company's compliance with Rule 13.24

[illegible]

(a) Sufficient Level of Operations



	For the year ended December 31, 2022	For the year ended December 31, 2021
	[illegible]	[illegible]
	[illegible]	[illegible]
	[illegible]	[illegible]
	[illegible]	[illegible]
	[illegible]	[illegible]
	[illegible]	[illegible]

	For the year ended December 31, 2022	For the year ended December 31, 2021
Inpatients		
[illegible]	[illegible]	[illegible]
[illegible] (%)	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]
Outpatients		
[illegible]	[illegible]	[illegible]

[illegible]

[illegible]

[illegible]

(b) Sufficient Assets

[illegible]

	For the year ended December 31, 2022 (RMB'000)	For the year ended December 31, 2021 (RMB'000)
[illegible]	[illegible]	[illegible]

	As at December 31, 2022 (RMB'000)	As at December 31, 2021 (RMB'000) (Restated)
[illegible]	[illegible]	[illegible]

[illegible]

(vi) Announce all material information for the Company's shareholders and investors to appraise its position

[illegible]

RESUMPTION OF TRADING

[illegible]